FISH Generates Reagent Revenue
Company Raises FY2007 Targets
BEIJING, Nov. 20 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic products and high intensity focused ultrasound tumor therapy system, today announced its unaudited financial results for the second quarter ended September 30, 2007 (''2Q FY2007''). The Company's 2007 fiscal year ends on March 31, 2008.
2Q FY2007 Highlights
-- Net revenues increased by 63.5% year-over-year to RMB214.9 million
-- Non-GAAP adjusted net income, as defined below, increased by 38.8%
year-over-year to RMB105.1 million (US$14.0 million).
-- Non-GAAP adjusted diluted earnings per ADS*, as defined below,
increased by 37.5% year-over-year to RMB3.78 (US$0.50).
* One American Depositary Share (''ADS'') = 10 ordinary shares
See ''Non-GAAP Measure Disclosures'' below, where the impact of certain items on reported results is discussed.
''We are pleased to report another strong quarter,'' commented Mr.
Xiaodong Wu, Chairman and CEO of the Company. ''Our FISH equipment has been
placed with over 100 leading hospitals and has generated recurring reagent
revenue in September quarter. We expect the FISH reagent revenue to
increase rapidly in the following quarters. We are also encouraged by the
approval of the Korean FDA on our HIFU system after receipt of the
conditional approval from the US FDA for our IDE application. We believe
the benefits of HIFU treatment for cancer patients will be graduall
|SOURCE China Medical Technologies, Inc.|
Copyright©2007 PR Newswire.
All rights reserved